Zhengye Biotechnology Holding (ZYBT) Receivables - Net (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Receivables - Net for 3 consecutive years, with $5.1 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net fell 51.61% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (down 51.61% YoY) and the FY2025 annual result came in at $5.2 million, down 50.13% from the prior year.
• Receivables - Net fell to $5.1 million in Q4 2025 per ZYBT's latest filing, from $7.4 million in the prior quarter.
• Over the last five years, Receivables - Net for ZYBT reached as high as $12.9 million in Q4 2023 and fell as low as $5.1 million in Q4 2025.
• A 3-year average of $9.0 million and a median of $9.0 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net decreased 17.42% — and 2025, when it sank 51.61%.
• Year by year, Receivables - Net stood at $12.9 million in 2023, then declined by 17.42% to $10.6 million in 2024, then plunged by 51.61% to $5.1 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $5.1 million, $7.4 million, and $10.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.